Amgen Inc. (AMGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Amgen Inc. executives, presenting at the Morgan Stanley Global Healthcare Conference, reported robust second-quarter financial results, including a 9% revenue increase, 13% volume growth, and a 21% rise in non-GAAP EPS. The company highlighted that 15 products achieved double-digit growth, with 14 products annualizing over $1 billion, notably driven by Repatha and EVENITY, which saw over 30% growth. This performance underscores Amgen's strong execution across its diverse therapeutic and biosimilar portfolios.

Analysis

Amgen's management presented a compelling case for strong operational momentum at the Morgan Stanley conference, underpinned by robust second-quarter results. The company reported a 9% year-over-year revenue increase, which was significantly driven by a 13% surge in product volume, indicating healthy underlying demand rather than just price increases. This top-line strength translated directly to the bottom line, with non-GAAP EPS growing by an impressive 21%. The performance is broad-based across the portfolio, a key highlight being that 15 products achieved double-digit growth and 14 products are now annualizing at over $1 billion in sales. Growth is being led by key assets in general medicine, specifically Repatha and EVENITY, which both delivered growth rates exceeding 30%. This update reinforces the success of Amgen's strategy focused on innovation across its four core therapeutic areas and its biosimilars business, demonstrating effective execution and a deep, diversified revenue stream.

Key Decisions for Investors

• Given the strong operational execution evidenced by 21% non-GAAP EPS growth and 13% volume expansion, investors should review their models to ensure they fully capture Amgen's near-term earnings power.
• The sustainability of the company's growth trajectory is heavily reliant on key products like Repatha and EVENITY; their continued performance above 30% growth should be a primary monitoring point for forward-looking estimates.
• While the portfolio's breadth with 14 billion-dollar products mitigates single-asset risk, the divergence between volume and revenue growth warrants scrutiny of net pricing trends to accurately assess the quality and durability of future earnings.